Target mRNA inhibition by oligonucleotide drugs in man

Nucleic Acids Research

Volumn 40, Issue 21, 2012, Pages 10585-10595

  Lightfoot, Helen L ^a   Hall, Jonathan ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ALN RSV 01; ALN TTR02; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; ARCHEXIN; AVI 4126; CHEMOKINE RECEPTOR CCR3; CUSTIRSEN; DRISAPERSEN; DYSTROPHIN; ETEPLIRSEN; GATAPARSEN; GTI 2040; INITIATION FACTOR 4E; ISIS 113715; ISIS 23722; ISIS CRPR; LY 2275796; MESSENGER RNA; MIPOMERSEN; MIRAVIRSEN; OBLIMERSEN; OGX 427; PF 655; PROTEIN BCL 2; SURVIVIN; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TPI ASM8; TRABEDERSEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC ASTHMA; AMYLOIDOSIS; APOPTOSIS; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CONTINUOUS INFUSION; DIABETIC MACULAR EDEMA; DNA SEQUENCE; DOSE RESPONSE; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; FAMILIAL HYPERCHOLESTEROLEMIA; GENE DELETION; GENE MUTATION; HEPATITIS C; HUMAN; ILEITIS; LOADING DRUG DOSE; LUNG CANCER; MULTIPLE MYELOMA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR;

CLINICAL TRIALS AS TOPIC; DOWN-REGULATION; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PROTEINS; RNA, MESSENGER;

EID: 84870579500     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gks861     Document Type: Review

References (70)

1. Kole, R., Krainer, A.R. and Altman, S. (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov., 11, 125-140.
2. Stein, C.A. and Goel, S. (2011) Therapeutic oligonucleotides: the road not taken. Clin. Cancer Res., 17, 6369-6372.
3. Gashaw, I., Ellinghaus, P., Sommer, A. and Asadullah, K. (2011) What makes a good drug target? Drug Discov. Today, 16, 1037-1043.
4. Knowles, J. and Gromo, G. (2003) A guide to drug discovery: target selection in drug discovery. Nat. Rev. Drug Discov., 2, 63-69. (Pubitemid 37361625)
5. Lindsay, M.A. (2003) Innovation: target discovery. Nat. Rev. Drug Discov., 2, 831-838.
6. Betz, U.A.K., Farquhar, R. and Ziegelbauer, K. (2005) Genomics: success or failure to deliver drug targets? Curr. Opin. Chem. Biol., 9, 387-391. (Pubitemid 41019685)
7. Berggren, R., Møller, M., Moss, R., Poda, P. and Smietana, K. (2012) Outlook for the next 5 years in drug innovation. Nat. Rev. Drug Discov., 11, 435-436.
8. Bennett, C.F. and Swayze, E.E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol., 50, 259-293.
9. Crooke, R.M. and Graham, M.J. (2011) Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia. Clin. Lipidol., 6, 675-692.
10. Raal, F.J., Santos, R.D., Blom, D.J., Marais, A.D., Charng, M.-J., Cromwell, W.C., Lachmann, R.H., Gaudet, D., Tan, J.L., Chasan-Taber, S. et al. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomized, double-blind, placebo-controlled trial. Lancet, 375, 998-1006.
11. Kastelein, J.J., Wedel, M.K., Baker, B.F., Su, J., Bradley, J.D., Yu, R.Z., Chuang, E., Graham, M.J. and Crooke, R.M. (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation, 114, 1729-1735. (Pubitemid 44607121)
12. Akdim, F., Tribble, D.L., Flaim, J.D., Yu, R., Su, J., Geary, R.S., Baker, B.F., Fuhr, R., Wedel, M.K. and Kastelein, J.J.P. (2011) Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur. Heart J., 32, 2650-2659.
13. Akdim, F., Stroes, E.S.G., Sijbrands, E.J.G., Tribble, D.L., Trip, M.D., Jukema, J.W., Flaim, J.D., Su, J., Yu, R., Baker, B.F. et al. (2010) Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol., 55, 1611-1618.
14. Visser, M.E., Wagener, G., Baker, B.F., Geary, R.S., Donovan, J.M., Beuers, U.H.W., Nederveen, A.J., Verheij, J., Trip, M.D., Basart, D.C.G. et al. (2012) Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur. Heart J., 33, 1142-1149.
15. Visser, M.E., Kastelein, J.J.P. and Stroes, E.S.G. (2010) Apolipoprotein B synthesis inhibition: results from clinical trials. Curr. Opin. Lipidol., 21, 319-323.
16. Dominski, Z. and Kole, R. (1993) Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. U.S.A, 90, 8673-8677. (Pubitemid 23277732)
17. Muntoni, F. and Wood, M.J. (2011) Targeting RNA to treat neuromuscular disease. Nat. Rev. Drug Discov., 10, 621-637.
18. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M.E., Bourke, J., Wells, D.J. et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet, 378, 595-605.
19. Goemans, N.M., Tulinius, M., van den Akker, J.T., Burm, B.E., Ekhart, P.F., Heuvelmans, N., Holling, T., Janson, A.A., Platenburg, G.J., Sipkens, J.A. et al. (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med., 364, 1513-1522.
20. Joudeh, J. and Claxton, D. (2012) Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms. Expert Opin. Investig. Drugs, 21, 363-373.
21. Jahrsdorfer, B., Jox, R., Muhlenhoff, L., Tschoep, K., Krug, A., Rothenfusser, S., Meinhardt, G., Emmerich, B., Endres, S. and Hartmann, G. (2002) Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J. Leukocyte Biol., 72, 83-92.
22. Wacheck, V., Krepler, C., Strommer, S., Heere-Ress, E., Klem, R., Pehamberger, H., Eichler, H.-G. and Jansen, B. (2002) Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice. Antisense Nucleic Acid Drug Dev., 12, 359-367. (Pubitemid 36169194)
23. Advani, P.P., Paulus, A., Masood, A., Sher, T. and Chanan-Khan, A. (2011) Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. Expert Opin. Drug Metab. Toxicol., 7, 765-774.
24. Rheingold, S.R., Hogarty, M.D., Blaney, S.M., Zwiebel, J.A., Sauk-Schubert, C., Chandula, R., Krailo, M.D. and Adamson, P.C. (2007) Phase I trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a children's oncology group study. J. Clin. Oncol., 25, 1512-1518. (Pubitemid 46733077)
25. Marcucci, G., Byrd, J.C., Dai, G., Klisovic, M.I., Kourlas, P.J., Young, D.C., Cataland, S.R., Fisher, D.B., Lucas, D., Chan, K.K. et al. (2003) Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood, 101, 425-432. (Pubitemid 36077559)
26. Marcucci, G., Stock, W., Dai, G., Klisovic, R.B., Liu, S., Klisovic, M.I., Blum, W., Kefauver, C., Sher, D.A., Green, M. et al. (2005) Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol., 23, 3404-3411.
27. Church, D.N. and Talbot, D.C. (2012) Survivin in solid tumors: rationale for development of inhibitors. Curr. Oncol. Rep., 14, 120-128.
28. Talbot, D.C., Ranson, M., Davies, J., Lahn, M., Callies, S., André , V., Kadam, S., Burgess, M., Slapak, C., Olsen, A.L. et al. (2010) Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin. Cancer Res., 16, 6150-6158.
29. Saleem, A., Matthews, J.C., Ranson, M., Callies, S., Andre, V., Lahn, M., Dickinson, C., Prenant, C., Brown, G., McMahon, A. et al. (2011) Molecular imaging and pharmacokinetic analysis of carbon-11 labeled antisense oligonucleotide LY2181308 in cancer patients. Theranostics, 1, 290-301.
30. Holmes, D. (2012) Cancer drug's survivin suppression called into question. Nat. Med., 18, 842-843.
31. Zoubeidi, A., Chi, K. and Gleave, M. (2010) Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin. Cancer Res., 16, 1088-1093.
32. Chi, K.N., Eisenhauer, E., Fazli, L., Jones, E.C., Goldenberg, S.L., Powers, J., Tu, D. and Gleave, M.E. (2005) A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 20-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst., 97, 1287-1296. (Pubitemid 41535369)
33. Chi, K.N., Siu, L.L., Hirte, H., Hotte, S.J., Knox, J., Kollmansberger, C., Gleave, M., Guns, E., Powers, J., Walsh, W. et al. (2008) A phase I study of OGX-011, a 20-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin. Cancer Res., 14, 833-839. (Pubitemid 351231167)
34. Laskin, J.J., Nicholas, G., Lee, C., Gitlitz, B., Vincent, M., Cormier, Y., Stephenson, J., Ung, Y., Sanborn, R., Pressnail, B. et al. (2012) Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platiunum regimen in patients with previously untreated advanced non-small cell lung cancer. J. Thorac. Oncol., 7, 579-586.
35. Saad, F., Hotte, S., North, S., Eigl, B., Chi, K., Czaykowski, P., Wood, L., Pollak, M., Berry, S., Lattouf, J.-B. et al. (2011) Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin. Cancer Res., 17, 5765-5773.
36. Chia, S., Dent, S., Ellard, S., Ellis, P.M., Vandenberg, T., Gelmon, K., Powers, J., Walsh, W., Seymour, L. and Eisenhauer, E.A. (2009) Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin. Cancer Res., 15, 708-713.
37. Hotte, S.J., Yu, E.Y., Hirte, H.W., Higano, C.S., Gleave, M. and Chi, K.N. (2009) OGX-427, a 20-methoxyethyl antisense oligonucleotide (ASO), against HSP27: results of a first-in-human trial. J. Clin. Oncol., 27(Suppl. 15 s), Abstr. 3506.
38. Zoubeidi, A. and Gleave, M. (2012) Small heat shock proteins in cancer therapy and prognosis. Int. J. Biochem. Cell Biol., 10, 1646-1656.
39. De Benedetti, A. and Graff, J.R. (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene, 23, 3189-3199. (Pubitemid 38638830)
40. Hong, D.S., Kurzrock, R., Oh, Y., Wheler, J., Naing, A., Brail, L., Callies, S., Andre, V., Kadam, S.K., Nasir, A. et al. (2011) A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin. Cancer Res., 17, 6582-6591.
41. Cerqueira, N.M., Pereira, S., Fernandes, P.A. and Ramos, M.J. (2005) Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. Curr. Med. Chem., 12, 1283-1294. (Pubitemid 40711424)
42. Heidel, J.D., Liu, J.Y., Yen, Y., Zhou, B., Heale, B.S., Rossi, J.J., Bartlett, D.W. and Davis, M.E. (2007) Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin. Cancer Res., 13, 2207-2215. (Pubitemid 46649891)
43. Klisovic, R.B., Blum, W., Wei, X., Liu, S., Liu, Z., Xie, Z., Vukosavljevic, T., Kefauver, C., Huynh, L., Pang, J. et al. (2008) Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin. Cancer Res., 14, 3889-3895.
44. Juhasz, A., Vassilakos, A., Chew, H.K., Gandara, D. and Yen, Y. (2006) Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol. Rep., 15, 1299-1304.
45. Sridhar, S.S., Canil, C.M., Chi, K.N., Hotte, S.J., Ernst, S., Wang, L., Chen, E.X., Juhasz, A., Yen, Y., Murray, P. et al. (2011) A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemother. Pharmacol., 67, 927-933.
46. Molfino, N.A., Gossage, D., Kolbeck, R., Parker, J.M. and Geba, G.P. (2012) Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin. Exp. Allergy, 42, 712-737.
47. Gauvreau, G.M., Boulet, L.P., Cockcroft, D.W., Baatjes, A., Cote, J., Deschesnes, F., Davis, B., Strinich, T., Howie, K., Duong, M. et al. (2008) Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am. J. Respir. Crit. Care Med., 177, 952-958. (Pubitemid 351717588)
48. Imaoka, H., Campbell, H., Babirad, I., Watson, R.M., Mistry, M., Sehmi, R. and Gauvreau, G.M. (2011) TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge. Clin. Exp. Allergy, 41, 1740-1746.
49. Gauvreau, G.M., Pageau, R., Seguin, R., Carballo, D., Gauthier, J., D'Anjou, H., Campbell, H., Watson, R., Mistry, M., Parry-Billings, M. et al. (2011) Dose-response effects of TPI ASM8 in asthmatics after allergen. Allergy (Oxford, UK), 66, 1242-1248.
50. Philpott, J.R. and Miner, P.B. Jr (2008) Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD. Expert Opin. Biol. Ther., 8, 1627-1632.
51. Yacyshyn, B.R., Bowen-Yacyshyn, M.B., Jewell, L., Tami, J.A., Bennett, C.F., Kisner, D.L. and Shanahan, W.R. Jr. (1998) A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology, 114, 1133-1142. (Pubitemid 28243898)
52. Jones, D. (2011) The long march of antisense. Nat. Rev. Drug Discov., 10, 401-402.
53. van Deventer, S.J.H., Tami, J.A. and Wedel, M.K. (2004) A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut, 53, 1646-1651. (Pubitemid 39434109)
54. Miner, P., Wedel, M., Bane, B. and Bradley, J. (2004) An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol. Ther., 19, 281-286. (Pubitemid 38253502)
55. Davis, M.E., Zuckerman, J.E., Choi, C.-H.J., Seligson, D., Tolcher, A., Alabi, C.A., Yen, Y., Heidel, J.D. and Ribas, A. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (London, UK), 464, 1067-1070.
56. Janssen, H.L., Reesink, H.W., Zeuzem, S., Lawitz, E., Rodriguez-Torres, M., Chen, A., Davis, C., King, B., Levin, A.A. and Hodges, M.R. (2011) Randomized, double-blind, placebo-controlled safety, anti-viral, proof of concept study of miravirsen, an oligonucleotide targeting miR-122, in treatment-naive patients with genotype 1 chronic HCV infection. Hepatology, 54(Suppl. 4), Abstr. LB-6.
57. Hau, P., Jachimczak, P. and Bogdahn, U. (2009) Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides. Expert Rev. Anticancer Ther., 9, 1663-1674.
58. Wick, W. and Weller, M. (2011) Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011; 13:132-142). Neuro-Oncol., 13, 559-560; author reply 561-562.
59. DeVincenzo, J., Cehelsky, J.E., Alvarez, R., Elbashir, S., Harborth, J., Toudjarska, I., Nechev, L., Murugaiah, V., Van Vliet, A., Vaishnaw, A.K. et al. (2008) Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res., 77, 225-231.
60. DeVincenzo, J., Lambkin-Williams, R., Wilkinson, T., Cehelsky, J., Nochur, S., Walsh, E., Meyers, R., Gollob, J. and Vaishnaw, A. (2010) A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl. Acad. Sci. USA, 107, 8800-8805.
61. Zamora, M.R., Budev, M., Rolfe, M., Gottlieb, J., Humar, A., DeVincenzo, J., Vaishnaw, A., Cehelsky, J., Albert, G., Nochur, S. et al. (2011) RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med., 183, 531-538.
62. Grillone, L.R. and Lanz, R. (2001) Fomivirsen. Drugs Today, 37, 245-255. (Pubitemid 32506283)
63. Summerton, J. and Weller, D. (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev., 7, 187-195. (Pubitemid 27323077)
64. Obika, S., Nanbu, D., Hari, Y., Morio, K.-I., In, Y., Ishida, T. and Imanishi, T. (1997) Synthesis of 20-O, 40-C-methyleneuridine and-cytidine. Novel bicyclic nucleosides having a fixed C3,-endo sugar puckering. Tetrahedron Lett., 38, 8735-8738. (Pubitemid 27504436)
65. Koshkin, A.A., Singh, S.K., Nielsen, P., Rajwanshi, V.K., Kumar, R., Meldgaard, M., Olsen, C.E. and Wengel, J. (1998) LNA (Locked Nucleic Acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron, 54, 3607-3630. (Pubitemid 28108183)
66. Martin, P. (1995) New access to 20-O-alkylated ribonucleosides and properties of 20-O-alkylated oligoribonucleotides. Helv. Chim. Acta, 78, 486-504.
67. Ming, X. (2011) Cellular delivary of siRNA and antisense oligonucleotides via receptor-mediated endocytosis. Expert Opin. Drug Deliv., 8, 435-449.
68. Geary, R.S., Yu, R.Z., Siwkowski, A. and Levin, A.A. (2007) Pharmacokinetics/pharmacodynamic properties of phosphorothioate 20-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man. In: Crooke, S.T. (ed.), Antisense Drug Technology: Principles, Strategies And Applications. Taylor & Francis Group, Boca Raton, pp. 305-326.
69. Swinney, D.C. and Anthony, J. (2011) How were new medicines discovered? Nat. Rev. Drug Discov., 10, 507-519.
70. Stadler, W.M., Desai, A.A., Quinn, D.I., Bukowski, R., Poiesz, B., Kardinal, C.G., Lewis, N., Makalinao, A., Murray, P. and Torti, F.M. (2008) A phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother. Pharmacol., 61, 689-694.